Substituted bridged urea analogs as sirtuin modulators
US-9834558-B2 · Dec 5, 2017 · US
Substituted bridged urea analogs as sirtuin modulators
US10072011B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10072011-B2 |
| Application number | US-201515527581-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 19, 2015 |
| Priority date | Nov 19, 2014 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound or pharmaceutically acceptable salt thereof, selected from
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
- C07D487/18Primary
Bridged systems · CPC title
- C07D471/18Primary
Bridged systems · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10072011B2 cover?
- The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide vari…
- Who is the assignee on this patent?
- Glaxosmithkline Ip No 2 Ltd, Glaxosmithkline Ip No 2 Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D487/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).